ArticleJournal of the American Heart Association2022
Sacubitril/Valsartan in Patients With Heart Failure and Concomitant End-Stage Kidney Disease.
Article in Journal of the American Heart Association, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 34 papers, 6 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
34 citing papers in PubMed, 6 syntheses or guidelines pooled it, 57 citations in OpenAlex.
- Efficacy and safety of angiotensin receptor-neprilysin inhibition in heart failure patients with end-stage kidney disease on maintenance dialysis: A systematic review and meta-analysis.European journal of heart failure · 2025Pooled it
- The role of sacubitril/valsartan in abnormal renal function patients combined with heart failure: a meta-analysis and systematic analysis.Renal failure · 2024Pooled it
- A meta-analysis investigating the efficacy and adverse events linked to sacubitril-valsartan in various heart failure subtypes.Clinical cardiology · 2024Pooled it
- Safety and efficacy of angiotensin receptor neprilysin inhibitor in improving cardiac function and blood pressure in dialysis patients.Frontiers in medicine · 2024Pooled it
- The efficacy and safety of sacubitril/valsartan in chronic kidney disease: a systematic review and meta-analysis.International urology and nephrology · 2024Pooled it
- Efficacy and safety of sacubitril/valsartan in patients on peritoneal dialysis: a systematic review and meta-analysis.Jornal brasileiro de nefrologiaPooled it
- Bibliometric analysis of sacubitril/valsartan in the management of chronic kidney disease (2013-2025).Renal failure · 2026Review
- Sacubitril/Valsartan in Patients with HFrEF Undergoing Maintenance Hemodialysis, Evidence of Cardiac Reverse Remodeling During 12-Month Follow-Up: Case Series.Reports (MDPI) · 2026Article
- Population Pharmacokinetics of Sacubitril/Valsartan in Patients with Heart Failure and End-Stage Renal Disease Undergoing Peritoneal Dialysis.Clinical pharmacokinetics · 2026Observational
- Severe Metabolic Decompensation in Metastatic Sarcomatoid Renal Cell Carcinoma During Immune Checkpoint Inhibitor Therapy: A Case Report and Literature Review.Diagnostics (Basel, Switzerland) · 2026Article
- Dose reduction and discontinuation of sacubitril/valsartan over time in patients undergoing maintenance hemodialysis.Frontiers in cardiovascular medicine · 2026Article
- What to do with key cardiovascular drugs when kidney function worsens?Clinical kidney journal · 2026Review
- Angiotensin receptor-neprilysin inhibitors in concurrent heart failure with reduced ejection fraction and kidney failure.ESC heart failure · 2025Article
- Breaking barriers: Neprilysin inhibition in chronic cardiorenal syndrome.World journal of cardiology · 2025Review
- The association of vascular access flow with sacubitril/valsartan and left ventricular ejection fraction in hemodialysis patients with heart failure with reduced ejection fraction.Clinical kidney journal · 2025Article
- Sacubitril/valsartan in a wide spectrum of heart failure patients (from mechanisms of action to outcomes in specific populations).Heart failure reviews · 2025Review
- Sacubitril/Valsartan in Dialysis Patients: Update on Current Perspectives.Cardiovascular drugs and therapy · 2025Review
- Heart failure with reduced ejection fraction and chronic kidney disease: a focus on therapies and interventions.Heart failure reviews · 2025Review
- Article
- Management of patients with heart failure and chronic kidney disease.Heart failure reviews · 2024Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors at 3 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background Heart failure with reduced ejection fraction (HFrEF) is a chronic disease with substantial mortality. Management of HFrEF has seen significant breakthrough after the launch of neprilysin inhibitor. The PARADIGM-HF (Prospective Comparison of ARNI with ACEI to Determine Impacton Global Mortality and Morbidity in Heart Failure) trial showed that sacubitril/valsartan significantly reduces HFrEF mortality and the heart failure hospitalization rate. However, in patients with advanced kidney disease, who have the highest prevalence of heart failure, the efficacy and safety of sacubitril/valsartan remains uncertain. We aim to study the efficiency of sacubitril/valsartan in patients with end-stage kidney disease. Methods and Results Heart function was screened by echocardiogram among all patients with end-stage kidney disease in 2 hospitals. Patients with HFrEF received either sacubitril/valsartan or conventional treatment. Fifteen echocardiographic parameters were compared before and after treatment. After 1-year sacubitril/valsartan treatment, parameters of systolic (left ventricular ejection fraction 31.3% to 45.1%,
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.